Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017, Article ID 1754696, 8 pages
https://doi.org/10.1155/2017/1754696
Research Article

Association between Recipient IL-15 Genetic Variant and the Prognosis of HBV-Related Hepatocellular Carcinoma after Liver Transplantation

1Department of Hepatobiliary Pancreatic Surgery, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
2Department of General Surgery, Hainan Cancer Hospital, Haikou, China

Correspondence should be addressed to Junwei Fan; moc.361@103088wjnaf and Zhihai Peng; moc.361@8591hzgnep

Received 2 June 2017; Revised 20 August 2017; Accepted 14 September 2017; Published 15 October 2017

Academic Editor: Yi-Chia Huang

Copyright © 2017 Tao Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global cancer statistics, 2012,” CA: a Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. H. B. El-Serag, “Hepatocellular carcinoma,” New England Journal of Medicine, vol. 365, no. 12, pp. 1118–1127, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Y. Yao, L. Xiao, N. M. Bass, R. Kerlan, N. L. Ascher, and J. P. Roberts, “Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging,” American Journal of Transplantation, vol. 7, no. 11, pp. 2587–2596, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. V. Mazzaferro, J. M. Llovet, R. Miceli et al., “Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis,” The Lancet Oncology, vol. 10, no. 1, pp. 35–43, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. J. P. Duffy, A. Vardanian, E. Benjamin et al., “Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA,” Annals of Surgery, vol. 246, no. 3, pp. 502–511, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Duvoux, F. Roudot-Thoraval, T. Decaens et al., “Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria,” Gastroenterology, vol. 143, no. 4, pp. 986–994.e3, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Hameed, N. Mehta, G. Sapisochin, J. P. Roberts, and F. Y. Yao, “Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria,” Liver Transplantation, vol. 20, no. 8, pp. 945–951, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. A. R. Hakeem, R. S. Young, G. Marangoni, J. P. Lodge, and K. R. Prasad, “Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma,” Alimentary Pharmacology & Therapeutics, vol. 35, no. 9, pp. 987–999, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Bruix and J. M. Llovet, “Major achievements in hepatocellular carcinoma,” The Lancet, vol. 373, no. 9664, pp. 614–616, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Chen, S. Liu, S. Chen et al., “Donor interleukin 6 gene polymorphisms predict the recurrence of hepatocellular carcinoma after liver transplantation,” International Journal of Clinical Oncology, vol. 21, no. 6, pp. 1111–1119, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Fuchs, W. Vermi, J. S. Lee et al., “Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells,” Immunity, vol. 38, no. 4, pp. 769–781, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Dubois, J. Mariner, T. A. Waldmann, and Y. Tagaya, “IL-15Rα recycles and presents IL-15 in trans to neighboring cells,” Immunity, vol. 17, no. 5, pp. 537–547, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Zhang, R. Sun, H. Wei, and Z. Tian, “Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy,” Haematologica, vol. 89, no. 3, pp. 338–347, 2004. View at Google Scholar
  14. T. A. Waldmann, “The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design,” Nature Reviews Immunology, vol. 6, no. 8, pp. 595–601, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Jiang, J. Zhang, and Z. Tian, “Functional characterization of interleukin-15 gene transduction into the human natural killer cell line NKL,” Cytotherapy, vol. 10, no. 3, pp. 265–274, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. T. A. Waldmann, “Interleukin-15 in the treatment of cancer,” Expert Review of Clinical Immunology, vol. 10, no. 12, pp. 1689–1701, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Zhou, H. Huang, J. Shi et al., “Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection,” Gut, vol. 59, no. 12, pp. 1699–1708, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. D. L. Blum, T. Koyama, A. E. M'Koma et al., “Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy,” Clinical Cancer Research, vol. 14, no. 23, pp. 7790–7797, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Budhu, M. Forgues, Q. H. Ye et al., “Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment,” Cancer Cell, vol. 10, no. 2, pp. 99–111, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Wang, N. Kato, Y. Hoshida et al., “Interleukin-1β gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection,” Hepatology, vol. 37, no. 1, pp. 65–71, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Migita, S. Miyazoe, Y. Maeda et al., “Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection—association between TGF-β1 polymorphisms and hepatocellular carcinoma,” Journal of Hepatology, vol. 42, no. 4, pp. 505–510, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Sun, M. Teng, J. Liu et al., “FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria,” Cancer Letters, vol. 306, no. 2, pp. 214–222, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Y. Yao, L. Ferrell, N. M. Bass et al., “Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival,” Hepatology, vol. 33, no. 6, pp. 1394–1403, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Gabriel, L. Ziaugra, and D. Tabbaa, “SNP genotyping using the Sequenom MassARRAY iPLEX platform,” Current Protocols in Human Genetics, vol. 60, pp. 2.12.1–2.12.18, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Y. Shi and L. He, “SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci,” Cell Research, vol. 15, no. 2, pp. 97-98, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. J. K. Yamamoto-Furusho, J. L. De-Leon-Rendon, E. Alvarez-Leon, M. Valdivia-Eziquio, C. Obil-Chavarria, and G. Vargas-Alarcon, “Association of the interleukin 15 (IL-15) gene polymorphisms with the risk of developing ulcerative colitis in Mexican individuals,” Molecular Biology Reports, vol. 41, no. 4, pp. 2171–2176, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. Z. Wu and Y. Xu, “IL-15Rα-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation,” Journal of Molecular Cell Biology, vol. 2, no. 4, pp. 217–222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Liu, L. Song, J. Wei et al., “IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity,” The Journal of Clinical Investigation, vol. 122, no. 6, pp. 2221–2233, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. K. B. Stephenson, N. G. Barra, E. Davies, A. A. Ashkar, and B. D. Lichty, “Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity,” Cancer Gene Therapy, vol. 19, no. 4, pp. 238–246, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. J. C. Morris, C. A. Ramlogan-Steel, P. Yu et al., “Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer,” Gene Therapy, vol. 21, no. 4, pp. 393–401, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. W. Jiang, C. Zhang, Z. Tian, and J. Zhang, “hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo,” Immunobiology, vol. 219, no. 7, pp. 547–553, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. K. L. Bondurant, A. Lundgreen, J. S. Herrick, S. Kadlubar, R. K. Wolff, and M. L. Slattery, “Interleukin genes and associations with colon and rectal cancer risk and overall survival,” International Journal of Cancer, vol. 132, no. 4, pp. 905–915, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. A. L. Van Dyke, M. L. Cote, A. S. Wenzlaff et al., “Cytokine and cytokine receptor single-nucleotide polymorphisms predict risk for non-small cell lung cancer among women,” Cancer Epidemiology, Biomarkers & Prevention, vol. 18, no. 6, pp. 1829–1840, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Dawidowska, M. Kosmalska, Ł. Sędek et al., “Association of germline genetic variants in RFC, IL15 and VDR genes with minimal residual disease in pediatric B-cell precursor ALL,” Scientific Reports, vol. 6, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. P. Fu, Y. Yi, J. L. Huang et al., “Prognostic nomograms stratify survival of patients with hepatocellular carcinoma without portal vein tumor thrombosis after curative resection,” The Oncologist, vol. 22, no. 5, pp. 561–569, 2017. View at Publisher · View at Google Scholar
  36. H. J. Choi, D. G. Kim, G. H. Na et al., “The clinical outcomes of patients with portal vein tumor thrombi after living-donor liver transplantation,” Liver Transplantation, vol. 23, no. 8, pp. 1023–1031, 2017. View at Publisher · View at Google Scholar
  37. V. G. Agopian, M. M. Morshedi, J. McWilliams et al., “Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients,” Annals of Surgery, vol. 262, no. 3, pp. 536–545, 2015. View at Publisher · View at Google Scholar · View at Scopus